HYDRINITY Launches RetaXome Retinal Pads and CÉLTHERA Overnight Cream

By Regina Bonham Bordeaux

September 14, 2026 · 6:29 p.m. ET

HYDRINITY has launched two overnight treatments with very different jobs. RetaXome Retinal Boost Treatment Pads combine retinal with five exfoliating acids, while CÉLTHERA Advanced Overnight Repair Cream pairs a barrier-supporting moisturizer base with newer exosome, NAD+ and “senolytic renewal” claims.¹

For shoppers, the formulas matter more than the regenerative language. The pads stack several potent actives in one leave-on step, while the cream makes technology and cellular-aging claims that go beyond what its ingredient list alone can establish.

What launched

RetaXome Retinal Boost Treatment Pads are leave-on pads used every three days. The ingredient list includes retinal plus glycolic, lactic, mandelic and salicylic acids and gluconolactone. Alcohol denat. is the second ingredient, and the formula also contains ectoin, hyaluronic acid, glycerin and other supporting ingredients.²

CÉLTHERA Advanced Overnight Repair Cream is used nightly. Its formula includes glycerin, squalane, niacinamide, urea, oligopeptide-1, hyaluronic acid, ectoin, four ceramides and cholesterol. HYDRINITY also markets the cream around ExoEGF technology, Centella secretomes, sunflower-derived NAD+ support and a “senolytic renewal” complex.³

Both products are available now through HYDRINITY’s website and professional-provider network.¹

Why it matters

RetaXome is not simply another retinal treatment. It combines retinal with five exfoliating acids in a leave-on pad, with alcohol denat. high on the ingredient list. That makes the every-third-night direction important, especially for shoppers whose routines already include retinoids, exfoliating acids or other potentially irritating treatments.²

CÉLTHERA has a more familiar foundation: humectants, emollients, niacinamide, ceramides and cholesterol give the formula a straightforward basis for moisturization and barrier support. The harder questions concern the claims layered on top of that foundation. Exosome delivery, NAD+ boosting and “senolytic” activity require finished-product evidence to show what they add beyond a well-formulated overnight moisturizer.³

What we know

HYDRINITY reports a 12-week multicenter randomized evaluation of the RetaXome pads in 30 participants ages 18 to 60 with sensitive or oily skin. The product page reports improvements in texture, overall appearance, visible pores, hyperpigmentation and redness. The public summary does not explain the randomization groups, comparator, statistical analysis or adverse-event findings, so the strength of those results cannot be fully assessed from the information currently posted.²

For CÉLTHERA, HYDRINITY describes a 12-week multicenter randomized study in 60 women ages 25 to 65. Some product-page results describe use of the cleanser followed by CÉLTHERA alone. Other results come from a regimen that also used RetaXome pads every third night. Those combination-regimen results cannot show how much of the reported change came from CÉLTHERA by itself.³

The launch announcement and official product pages verify the formulas, directions and claims HYDRINITY is making. They do not independently establish that biomimetic exosome delivery, NAD+ support or senolytic positioning gives either product a unique clinical advantage over other well-formulated retinal, exfoliating or barrier-support products.

What we’re watching

BB will be watching for fuller study documentation, including comparator details, statistical methods and tolerability reporting. That information would make it easier to judge the finished products rather than the marketing mechanisms around them.

The launch also makes exosome delivery, topical NAD+ support and senolytic skincare worth following as claims trends. As more products use this language, the useful question for shoppers is whether the finished formula has evidence showing a meaningful advantage—not simply whether the technology has a scientific-sounding name.